Laurent Levy

Laurent Levy was born on the outskirts of northern-east Paris, France, in Montreuil.

After high school, Laurent went on to study biology at Pierre and Marie Curie University (Paris VI). He changed his area of study to biophysics then to physics and chemistry after two years, graduating with his bachelor's degree in 1994. He then earned his master's degree (DEA) in physics of condensed matter from UPVI-ESPCI.{{cite journal | last1=Levy | first1=L. | last2=Hochepied | first2=J. F. | last3=Pileni | first3=M. P. | title=Control of the Size and Composition of Three Dimensionally Diluted Magnetic Semiconductor Clusters | journal=The Journal of Physical Chemistry | publisher=American Chemical Society (ACS) | volume=100 | issue=47 | year=1996 | issn=0022-3654 | doi=10.1021/jp960824w | pages=18322–18326 }}

Laurent attended Paris VI and the CEA for doctoral studies in physical chemistry, specializing in nanomaterials. His doctoral thesis centered on quantum confinement as it relates to magnetic semiconductors.{{cite journal | last1=Levy | first1=L. | last2=Feltin | first2=N. | last3=Ingert | first3=D. | last4=Pileni | first4=M. P. | title=Three Dimensionally Diluted Magnetic Semiconductor Clusters Cd1-yMnyS with a Range of Sizes and Compositions: Dependence of Spectroscopic Properties on the Synthesis Mode | journal=The Journal of Physical Chemistry B | publisher=American Chemical Society (ACS) | volume=101 | issue=45 | year=1997 | issn=1520-6106 | doi=10.1021/jp970978r | pages=9153–9160 }}

Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Prof. Paras N. Prasad at the Institute for Lasers, Photonics, and Biophotonics at SUNY Buffalo in the United States.{{cite web | title=The management | website=Nanobiotix | date=2019-02-28 | url=https://www.nanobiotix.com/management/ | ref={{sfnref | Nanobiotix | 2019}} | access-date=2020-03-06}}{{cite web | title=UB spinoff Nanobiotix looks to bring cancer treatment to market | website=University at Buffalo | date=2014-05-23 | url=http://www.buffalo.edu/news/releases/2014/05/035.html | ref={{sfnref | University at Buffalo | 2014}} | access-date=2020-03-06}}{{cite web | author=Reuters Editorial | title=Officer Profile - Quotes | website=IN | date=2020-03-05 | url=https://in.reuters.com/finance/stocks/officer-profile/NANOB.PA/1779494 | archive-url=https://web.archive.org/web/20200323010553/https://in.reuters.com/finance/stocks/officer-profile/NANOB.PA/1779494 | url-status=dead | archive-date=2020-03-23 | access-date=2020-03-06}}

In 2003, Levy founded Nanobiotix to create a medical treatment using the techniques he developed at SUNY Buffalo. Nanobiotix would build on his work to develop what is now known as NBTXR3, a first-in-class “radioenhancer” designed to significantly increase the efficacy of radiation therapy without increasing negative side effects associated with radiation. In 2011, Nanobiotix treated its first patient using NBTXR3. In 2018 the results of a phase III clinical trial established that this new type of product could work in humans. In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall.{{cite journal | last1=Bonvalot | first1=Sylvie | last2=Rutkowski | first2=Piotr L | last3=Thariat | first3=Juliette | last4=Carrère | first4=Sébastien | last5=Ducassou | first5=Anne | last6=Sunyach | first6=Marie-Pierre | last7=Agoston | first7=Peter | last8=Hong | first8=Angela | last9=Mervoyer | first9=Augustin | last10=Rastrelli | first10=Marco | last11=Moreno | first11=Victor | last12=Li | first12=Rubi K | last13=Tiangco | first13=Béatrice | last14=Herraez | first14=Antonio Casado | last15=Gronchi | first15=Alessandro | last16=Mangel | first16=László | last17=Sy-Ortin | first17=Teresa | last18=Hohenberger | first18=Peter | last19=Baère | first19=Thierry de | last20=Cesne | first20=Axel Le | last21=Helfre | first21=Sylvie | last22=Saada-Bouzid | first22=Esma | last23=Borkowska | first23=Aneta | last24=Anghel | first24=Rodica | last25=Co | first25=Ann | last26=Gebhart | first26=Michael | last27=Kantor | first27=Guy | last28=Montero | first28=Angel | last29=Loong | first29=Herbert H | last30=Vergés | first30=Ramona | last31=Lapeire | first31=Lore | last32=Dema | first32=Sorin | last33=Kacso | first33=Gabriel | last34=Austen | first34=Lyn | last35=Moureau-Zabotto | first35=Laurence | last36=Servois | first36=Vincent | last37=Wardelmann | first37=Eva | last38=Terrier | first38=Philippe | last39=Lazar | first39=Alexander J | last40=Bovée | first40=Judith V M G | last41=Péchoux | first41=Cécile Le | last42=Papai | first42=Zsusanna | title=NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial | journal=The Lancet Oncology | volume=20 | issue=8 | date=2019-08-01 | issn=1470-2045 | pmid=31296491 | doi=10.1016/S1470-2045(19)30326-2 | pages=1148–1159 | doi-access=free }}{{cite web | last=Swift | first=Diana | title=Novel Radioenhancer Boosts RT Response in Sarcoma | website=MedPage Today | date=2019-07-16 | url=https://www.medpagetoday.com/hematologyoncology/othercancers/81034 | access-date=2020-03-05}}{{cite journal |journal=Clinical Cancer Research| date=2016-12-22 | volume=23 | issue=4 | pages=908–917 | doi=10.1158/1078-0432.CCR-16-1297 | pmid=27998887 | title=First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas | last1=Bonvalot | first1=Sylvie | last2=Le Pechoux | first2=Cécile | last3=De Baere | first3=Thierry | last4=Kantor | first4=Guy | last5=Buy | first5=Xavier | last6=Stoeckle | first6=Eberhard | last7=Terrier | first7=Philippe | last8=Sargos | first8=Paul | last9=Coindre | first9=Jean Michel | last10=Lassau | first10=Nathalie | last11=Ait Sarkouh | first11=Rafik | last12=Dimitriu | first12=Mikaela | last13=Borghi | first13=Elsa | last14=Levy | first14=Laurent | last15=Deutsch | first15=Eric | last16=Soria | first16=Jean-Charles | doi-access=free }}{{cite web | author=Cynthia E. Keen| title=Potential benefits of adding radioenhancer nanoparticles to RT treatment for soft-tissue sarcoma | website=Applied Radiation Oncology | url=https://appliedradiationoncology.com/articles/potential-benefits-of-adding-radioenhancer-nanopartlcles-to-rt-treatment-for-soft-tissue-sarcoma | access-date=2020-03-05}}

In 2015 Levy joined the board of biotech startup Valbiotis, the first company to register a nutraceutical based on clinical findings. The company develops nutraceutical products for the prevention of diabetes in pre-diabetics. Levy helped take Valbiotis public in 2018.{{cite web | title=Research & Development Company | website=Valbiotis | date=2018-07-31 | url=https://www.valbiotis.com/en/ | ref={{sfnref | Valbiotis | 2018}} | access-date=2020-03-05}}{{cite web | title=VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes | website=BioSpace | date=2019-07-03 | url=https://www.biospace.com/article/valbiotis-announces-positive-results-from-the-phase-iia-clinical-study-of-valedia-now-the-first-product-proven-effective-in-people-with-prediabetes/ | ref={{sfnref | BioSpace | 2019}} | access-date=2020-03-05}}

In 2019, Levy co-founded the biotechnology company Curadigm as a spin-off from Nanobiotix. Curadigm's lead technology is a nanoprimer that affects liver function, reducing its ability to filter out drugs, making drug delivery more efficacious.{{cite web | title=Together to Reshape Healthcare Full Version | website=Curadigm | date=2019-05-17 | url=https://www.curadigm.com/ | ref={{sfnref | Curadigm | 2019}} | access-date=2020-03-05}}{{cite web | title=New Nanobiotix subsidiary to use 'nanoprimer' tech | website=The Pharma Letter | url=https://www.thepharmaletter.com/article/new-nanobiotix-subsidiary-to-use-nanoprimer-tech | access-date=2020-03-05}}{{cite journal | title=Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile - Scientific Reports | journal=Scientific Reports | date=19 March 2018 | volume=8 | issue=1 | pages=4797 | doi=10.1038/s41598-018-23140-9 | ref={{sfnref | Nature}} | last1=Pottier | first1=Agnès | last2=Levy | first2=Laurent | last3=Bergere | first3=Maxime | last4=Mpambani | first4=Francis | last5=Berjaud | first5=Céline | last6=Paolini | first6=Marion | last7=Poul | first7=Laurence | last8=Meyre | first8=Marie-Edith | last9=Germain | first9=Matthieu | pmid=29556068 | pmc=5859131 }}

As Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the European Union. To advocate for nanomedical development, Levy joined the European Technology Platform Nanomedicine (ETPN) in 2012 and was elected vice president.{{cite journal | last=Lévy | first=Laurent | title=Europe as leaders in nanomedicine: let's go for it! | journal=Nanomedicine | publisher=Future Medicine Ltd | volume=9 | issue=4 | year=2014 | issn=1743-5889 | doi=10.2217/nnm.14.14 | pages=389–391 | pmid=24787438 }}{{cite journal |last1=Eaton |first1=Michael A.W. |title=Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry |journal=Journal of Controlled Release |date=June 2012 |volume=164 |issue=3 |pages=370–371 |doi=10.1016/j.jconrel.2012.06.016 |pmid=22721816 |url=https://www.researchgate.net/publication/227856365 |access-date=5 March 2020}}{{cite journal |last1=Eaton |first1=Mike |title=Improving Innovation in Nano-Healthcare Funding |journal=Precision Nanomedicine |date=March 2018 |volume=1 |doi=10.29016/180108.1|doi-access=free }}

Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies. Levy also helped to establish the ETPN's Nanomedicine Translation Hub, which advises SMEs, Startups, Academics and Inventors on how to bring their nanomedicine projects to the market.{{cite web | title=HealthtechTAB | website=HealthtechTAB | date=2019-10-11 | url=https://healthtechtab.eu/ | ref={{sfnref | HealthtechTAB | 2019}} | access-date=2020-03-05}}{{cite web | title=ETPN | website=The Nanomedicine Translation Hub | url=https://etp-nanomedicine.eu/about-etpn/nanomedicine-translation-hub/ | ref={{sfnref | The Nanomedicine Translation Hub}} | access-date=2020-03-05}}

• 2019 Prix Galien{{cite news |title=Nanotech company Nanobiotix earns Prix Galien Award for innovation |url=https://appliedradiationoncology.com/articles/nanotech-company-nanobiotix-earns-prix-galien-award-for-innovation |access-date=5 March 2020 |publisher=Applied Radiation Oncology |date=Dec 17, 2019}}
• 2018
• CPhI Pharma Award - Excellence in Pharma: CEO of the year Laurent Levy
• CPhI Pharma Award - Pharma Company of the year : Nanobiotix
• European Business Award 2018 : The award for Innovation
• 2016 European Mediscience Award: Best technology Award
• 2015 Prix de la relation actionnaires
• 2013 University of Buffalo Young Entrepreneurs Prize : Laurent Levy{{cite web | title=Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award | website=Applied Sciences from Technology Networks | date=2013-04-04 | url=https://www.technologynetworks.com/applied-sciences/news/dr-laurent-levy-ceo-of-nanobiotix-receives-ub-entrepreneurship-award-192835 | ref={{sfnref | Applied Sciences from Technology Networks | 2013}} | access-date=2020-03-05}}
• 2006 Paris Bio Prize
• 2003 Inventor of the year: Niagara frontier intellectual property law association

• [https://www.youtube.com/watch?v=5KW_Vu1ZWgo Ted Talk]

• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009147214 NANOBIOTIX CORE TECHNOLOGY]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005120590 ACTIVATABLE PARTICLES]
• [https://patents.google.com/patent/WO2012104275A2 NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013087920 NANOPARTICLES COMPRISING METALLIC AND HAFNIUM OXIDE MATERIALS, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014114732 INORGANIC NANOPARTICLES COMPOSITIONS IN COMBINATION WITH IONIZING RADIATIONS FOR TREATING CANCER]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014202723 COMPOSITIONS AND METHODS FOR USE IN MEDICAL DIAGNOSIS]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014202738 COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015091888 PHARMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016189125 NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011003999&_cid=P12-K89CXB-80558-1 METALLIC NANOPARTICLES, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014191569&_cid=P12-K8H8M0-57242-1 WO/2014/191569: PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016083333&_cid=P12-K8H8VL-59699-1 PHARMACEUTICAL COMPOSITION COMBINING AT LEAST TWO DISTINCT NANOPARTICLES AND A PHARMACEUTICAL COMPOUND, PREPARATION AND USES THEREOF]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018114945&_cid=P12-K8H8YF-60579-1 NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018114988&_cid=P12-K8H912-61212-1 NANOPARTICLES FOR USE FOR ENHANCING BRAIN PERFORMANCES OR FOR TREATING STRESS]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018115023&_cid=P12-K8H94D-62030-1 COATED NANOPARTICLES FOR USE FOR MODULATING ELECTRICAL POLARIZATION OF NEURONS]
• [https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019121748&_cid=P12-K8H970-62548-1 NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER]

• {{cite journal | last1=Levy | first1=Laurent | last2=Sahoo | first2=Yudhisthira | last3=Kim | first3=Kyoung-Soo | last4=Bergey | first4=Earl J. | last5=Prasad | first5=Paras N. | title=Nanochemistry: Synthesis and Characterization of Multifunctional Nanoclinics for Biological Applications | journal=Chemistry of Materials | publisher=American Chemical Society (ACS) | volume=14 | issue=9 | year=2002 | issn=0897-4756 | doi=10.1021/cm0203013 | pages=3715–3721 }}
• {{cite journal | last1=Maggiorella | first1=Laurence | last2=Barouch | first2=Gilles | last3=Devaux | first3=Corinne | last4=Pottier | first4=Agnès | last5=Deutsch | first5=Eric | last6=Bourhis | first6=Jean | last7=Borghi | first7=Elsa | last8=Levy | first8=Laurent | title=Nanoscale radiotherapy with hafnium oxide nanoparticles | journal=Future Oncology | publisher=Future Medicine Ltd | volume=8 | issue=9 | year=2012 | issn=1479-6694 | doi=10.2217/fon.12.96 | pages=1167–1181 | pmid=23030491 }}
• {{cite journal | last1=Bergey | first1=Earl J. | last2=Levy | first2=Laurent | last3=Wang | first3=Xiaopeng | last4=Krebs | first4=Linda J. | last5=Lal | first5=Manjari | last6=Kim | first6=Kyoung-Soo | last7=Pakatchi | first7=Shadi | last8=Liebow | first8=Charles | last9=Prasad | first9=Paras N. | title = DC Magnetic Field Induced Magnetocytolysis of Cancer Cells Targeted by LH-RH Magnetic Nanoparticles in vitro |

journal=Biomedical Microdevices | publisher=Springer Science and Business Media LLC | volume=4 | issue=4 | year=2002 | issn=1387-2176 | doi=10.1023/a:1020906307053 | pages=293–299 | s2cid=134380514 }}

{{Reflist}}

{{Authority control}}

{{DEFAULTSORT:Levy, Laurent}}

Category:French physical chemists

Category:Pierre and Marie Curie University alumni

Category:French chief executives

Category:French healthcare chief executives

Category:French nanotechnologists

Category:1971 births

Category:Living people

Category:University at Buffalo alumni